| Literature DB >> 35311092 |
Jan Coburger1, Julia Onken2, Stefan Rueckriegel3, Christian von der Brelie4, Minou Nadji-Ohl5, Marie-Therese Forster6, Rüdiger Gerlach7, Meike Unteroberdörster2, Constantin Roder8, Katja Kniese9, Stefan Schommer5, Dietrich Rothenbacher10, Gabriele Nagel10, Christian Rainer Wirtz1, Ralf-Ingo Ernestus3, Arya Nabavi9, Marcos Tatagiba8, Marcus Czabanka6, Oliver Ganslandt5, Veit Rohde4, Mario Löhr3, Peter Vajkoczy2, Andrej Pala1.
Abstract
Majority of lower grade glioma (LGG) are located eloquently rendering surgical resection challenging. Aim of our study was to assess rate of permanent deficits and its predisposing risk factors. We retrieved 83 patients harboring an eloquently located LGGs from the prospective LoG-Glio Database. Patients without surgery or incomplete postoperative data were excluded. Sign rank test, explorative correlations by Spearman ρ and multivariable regression for new postoperative deficits were calculated. Eloquent region involved predominantly motor (45%) and language (40%). At first follow up after 3 months permanent neuro-logical deficits (NDs) were noted in 39%. Mild deficits remained in 29% and severe deficits in 10%. Complete tumor removal (CTR) was successfully in 62% of intended cases. Postoperative and 3-month follow up National Institute of Health Stroke Score (NIHSS) showed significantly lower values than preoperatively (p<0.001). 38% cases showed a decreased NIHSS at 3-month, while occurrence was only 14% at 9-12-month follow up. 6/7 patients with mild aphasia recovered after 9-12 months, while motor deficits present at 3-month follow up were persistent in majority of patients. Eastern oncology group functional status (ECOG) significantly decreased by surgery (p < 0.001) in 31% of cases. Between 3-month and 9-12-months follow up no significant improvement was seen. In the multivariable model CTR (p=0.019, OR 31.9), and ECOG>0 (p=0.021, OR 8.5) were independent predictors for permanent postoperative deficit according to NIHSS at 3-month according to multivariable regression model. Patients harboring eloquently located LGG are highly vulnerable for permanent deficits. Almost one third of patients have a permanent reduction of their functional status based on ECOG. Risk of an extended resection has to be balanced with the respective oncological benefit. Especially, patients with impaired pre-operative status are at risk for new permanent deficits. There is a relevant improvement of neurological symptoms in the first year after surgery, especially for patients with slight aphasia.Entities:
Keywords: LGG; awake surgery; eloquent area surgery; eloquent area tumours; iMRI = intraoperative MRI; iUS = intraoperative ultrasound; intraoperative monitoring (IOM); neurological deficit
Year: 2022 PMID: 35311092 PMCID: PMC8927728 DOI: 10.3389/fonc.2022.845992
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Patients´ and treatment characteristics.
| Variable | N (%) |
|---|---|
|
| 37 (44.6) |
|
| 14 (16.1) |
|
| 35 (42.7) |
|
| 12 (13.8) |
|
| 24 (27.6) |
|
| 12 (14.5) |
|
| |
| Frontal | 43 (51.8) |
| Parietal | 16 (19.3) |
| Temporal | 15 (18.1) |
| Occipital | 1 (1.2) |
| Other | 8 (9.6) |
|
| |
| Left | 46 (55.4) |
| Right | 36 (43.4) |
| Both | 1 (1.2) |
|
| |
| Seizure | 47 (56.6) |
| Headache | 7 (8.4) |
| Neurological deficit | 4 (4.8) |
| Incidental | 9 (10.8) |
| Others | 16 (19.3) |
|
| 25 (28.7) |
|
| 11 (12.6) |
|
| 22 (27.2), |
|
| 10 (11.5) |
|
| 19 (21.8) |
|
| 66 (75.9) |
|
| 22 (25.3) |
|
| 35 (40.2) |
|
| |
| Stereotactic biopsy | 8 (9.2) |
| Open biopsy | 3 (3.4) |
| Intended subtotal resection | 30 (34.5) |
| Intended complete tumor resection (CTR) | 42 (48.3) |
|
| 26 (29.9) |
|
| |
| None (wait and scan) | 26 (29.9) |
| Chemotherapy (CT) | 4 (4.6) |
| Radiotherapy (RT) | 10 (11.5) |
| Consecutive CT & RT | 17 (19.5) |
| Combined CT & RT | 25 (28.7) |
Surgical complications (CSF – cerebrospinal fluid).
| Complications | N (83) |
|---|---|
| Infection | 2.4% (2) |
| CSF Leakage | 1.2% (1) |
| Meningitis | 1.2% (1) |
| Ischemic lesion | 6.0% (5) |
| Hemorrhage | 3.6% (3) |
| Others | 2.4& (2) |
The Eastern Cooperative Oncology Group (ECOG) and National Institute for Stroke Scale (NIHSS) before surgery, at discharge and during follow up.
| ECOG | Before surgery (N=79) | At discharge (N=79) | 3-month follow up (N=75) | 9-12-month follow up (N=51) |
|---|---|---|---|---|
| 0 | 68.4% (54) | 40.5% (32) | 54.7% (41) | 41.0% (34) |
| 1 | 26.2% (21) | 41.8% (33) | 28.7% (29) | 16.9% (14) |
| 2 | 3.6% (3) | 15.2% (12) | 5.3% (4) | 3.6% (3) |
| 3 | 1.2% (1) | 2.5% (2) | 0 | 0 |
| 4 | 0 | 0 | 1.2% n (1) | 0 |
| 5 | 0 | 0 | 0 | 0 |
|
|
|
|
|
|
| 0 | 85.3% (64) | 50.7% (35) | 54.5% (42) | 86.3% (0) |
| 1 | 6.7% (5) | 26.1% (18) | 24.7% (19) | 5.9% (3) |
| 2 | 6.7% (5) | 5.8% (4) | 11.7% (9) | 2.0% (1) |
| 3 | 0 | 7.2% (5) | 0 | 2.0% (1) |
| 4 | 1.3% (1) | 1.4% (1) | 3.9% (3) | 3.9% (2) |
| >4 | 0 | 8.8% (6) | 5.2% (4) | 0 |
Figure 1Histogram comparing Eastern Oncology Group (ECOG) score and National institute of health score (NIHSS).
Figure 2Bar chart comparing proportions of decreased National institute of health score (NIHSS) at 3-month follow up compared to preoperative scores by complete tumor resection (CTR) according to radiological criteria.
Multivariable binary logistic regression for presence of new permanent neurological deficits at 3 months follow-up after surgery according to National Institute of Health Score.
| B | S.E. | Wald | df | Sig. | Odds Ratio (OR) | 95% C.I. for odds ratio | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||||
| IDH mutation positive | ,381 | 1,475 | ,067 | 1 | ,796 | 1,46 | ,081 | 26,361 | ||
| WHO grade III | ,422 | 1,095 | ,149 | 1 | ,700 | 1,53 | ,178 | 13,045 | ||
| Tumor location (frontal indicator) | 1,979 | 4 | ,740 | |||||||
| Parietal (1) | -1,678 | 1,269 | 1,749 | 1 | ,186 | ,19 | ,016 | 2,245 | ||
| Temporal (2) | -,419 | 1,134 | ,136 | 1 | ,712 | ,66 | ,071 | 6,075 | ||
| Insula (3) | -20,514 | 40192,970 | ,000 | 1 | 1,000 | ,000 | ,000 | . | ||
| Basal ganglia (4) | -,106 | 1,687 | ,004 | 1 | ,950 | ,90 | ,033 | 24,514 | ||
| Recurrent surgery | ,972 | 1,536 | ,400 | 1 | ,527 | 2,64 | ,130 | 53,612 | ||
| Awake surgery | 2,141 | 1,140 | 3,525 | 1 | ,060 | 8,51 | ,910 | 79,534 | ||
| Intraoperative monitoring | -,372 | 1,705 | ,048 | 1 | ,827 | ,69 | ,024 | 19,497 | ||
| Intraoperative ultrasound | 1,120 | 1,092 | 1,053 | 1 | ,305 | 3,07 | ,361 | 26,050 | ||
| Intraoperative MRI | ,185 | ,956 | ,037 | 1 | ,847 | 1,20 | ,185 | 7,841 | ||
| Complete tumor resection | 3,463 | 1,471 | 5,545 | 1 | ,019 | 31,917 | 1,787 | 569,731 | ||
| Age > 60 years (1) | ,760 | 1,239 | ,377 | 1 | ,539 | 2,149 | ,189 | 24,245 | ||
| Preoperatively impaired ECOG (>0) | 2,412 | 1,044 | 5,337 | 1 | ,021 | 11,16 | 1,442 | 86,398 | ||
| Preoperative deficits (NHISS >0) | -,379 | 1,689 | ,050 | 1 | ,822 | ,68 | ,025 | 18,745 | ||
| Type of surgery (indicator intended gross total resection) | ,559 | 3 | ,906 | |||||||
| Stereotactic biopsy (1) | -1,107 | 3,810 | ,084 | 1 | ,771 | ,33 | ,000 | 578,326 | ||
| Open biopsy (2) | -1,988 | 3,060 | ,422 | 1 | ,516 | ,14 | ,000 | 55,043 | ||
| Intended subtotal resection (3) | -1,909 | 2,947 | ,419 | 1 | ,517 | ,15 | ,000 | 47,800 | ||
| Adjuvant treatment (indicator not treatment) | 3,114 | 4 | ,539 | |||||||
| Chemotherapy (CT) (1) | 3,811 | 2,232 | 2,916 | 1 | ,088 | 45,21 | ,569 | 3590,943 | ||
| Radiotherapy (RT) (2) | ,665 | 1,454 | ,209 | 1 | ,647 | 1,95 | ,112 | 33,642 | ||
| Consecutive RT & CT (3) | ,939 | 1,200 | ,612 | 1 | ,434 | 2,56 | ,244 | 26,860 | ||
| Combined RT & CT (4) | ,798 | 1,379 | ,335 | 1 | ,563 | 2,22 | ,149 | 33,166 | ||
| Time to surgery > 3 months from primary diagnosis | -,658 | 1,094 | ,362 | 1 | ,548 | ,528 | ,061 | 4,423 | ||
| Constant | -1,966 | 2,392 | ,675 | 1 | ,411 | ,14 | ||||
IDH, Isocitrat dehydrogenase; WHO, World Health Organization; MRI, Magnetic resonance imaging; NHISS, National Institute of Health Stroke Score; ECOG, Eastern Oncology Group Status Score.